Skip to content

Silence Therapeutics

US · SLN #3615 by market cap
19.81 0.00 0.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 19.85 +0.20%
After-hours 19.81 0.00%
19.836.0019.812026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on SLN?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +131.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 3.9% of float.
  • Analyst tilt is Hold.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D

How much profit the business keeps from each dollar of sales and capital.

Gross margin 61.5% Better than 76%
Operating margin -16,056.0% Better than 1%
Net margin -15,851.9% Better than 1%
Return on equity -90.3% Better than 6%
Return on invested capital -92.8% Better than 2%
Momentum A+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 49.3% Better than 100%
6-month return 219.5% Better than 100%
12-month return (ex latest month) 211.7% Better than 99%
Distance below 52-week high 0.3% Better than 99%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 8.7x Better than 92%
Debt to assets 0.1% Better than 98%
Interest coverage -1,478.7x Better than 2%
Analyst View F

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 0.0% Better than 0%
Upside to average target 1.0% Better than 4%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -0.10%
1M +1.02%
3M +50.42%
6M +217.47%
YTD +225.82%
1Y +211.97%
3Y +99.90%
5Y -13.68%

Key statistics

Price & volume

Prev close
19.81
Open
19.81
Day range
19.80 - 19.83
Avg price
19.81
Volume
399.15K
Turnover
7.91M
Amplitude
0.15%
52-week range
4.19 - 19.87

Valuation

P/E
-10.48
P/E (TTM)
-18.87
P/B
-5.73
EPS
-1.89
Net profit
-117.56M
Net assets
-215.04M

Share structure

Market cap
1.23B
Float cap
993.90M
Shares out
62.20M
Float shares
50.17M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 100% of range
4.19 19.87

0.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-107.31M net over the window

Short interest

Shares short
2.42M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Silence Therapeutics (SLN)?

Silence Therapeutics last traded at 19.81. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Silence Therapeutics's market cap?

About 1.23B.

What is the P/E ratio of Silence Therapeutics?

The trailing twelve-month P/E is -18.87. The Valuation tab shows it against the stock's own five-year range.

Does Silence Therapeutics pay a dividend?

Silence Therapeutics does not currently pay a regular dividend.

Is Silence Therapeutics a buy according to analysts?

The consensus of 4 analysts is a Hold rating, with an average 12-month price target of 20.00, which implies 1.0% upside from the current price. This is not investment advice.

What is Silence Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Silence Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Silence Therapeutics discussion 0 comments

Add a comment